OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
TL;DR
- OpenAI announced its acquisition of Orchestra Bio on Tuesday.
- Orchestra Bio develops AI agents to aid biotech companies with drug discovery operations.
- The acquired team and technology will be integrated into OpenAI's Rosalind AI model and Rosalind Workbench tool.
- Rosalind aims to help researchers plan experiments and analyze results in life sciences.
- OpenAI has already secured customers like Moderna and Novo Nordisk for Rosalind.